In the world of science PR, it's not enough to have groundbreaking research – you need a story that grips. A narrative that not only informs but also intrigues. So how do you break through the clutter and make your science news sing?

rBIO's biosimilar insulin story landed in Wired, MedCity News, and more. See the PR tactics that drove success and get tips for your biotech launch.

CureLab Oncology’s DNA vaccine Elenagen, in combination with a proven chemotherapy, demonstrates promising clinical results against one of the deadliest forms of ovarian cancer.

It’s incredibly important to have a strong brand image and supporting story before you begin PR. Here are some of our recent branding and website success stories with some hugely promising science startups.

Gero is a cutting-edge biotechnology company dedicated to the mission of curing age-related human diseases and understanding, slowing, and even halting the aging process itself.

Cyclica will apply its AI-enabled drug discovery platform to discover new therapeutic options with the goal of expanding the range of accessible non-hormonal contraceptive choices for women in developing countries.

Two biotech leaders have embarked on a research project to streamline manufacturing of non-viral CRISPR gene editing components. Their goal is to improve the editing efficiency and cell viability of non-viral-based cell therapies.

The clinical benefits currently delivered for terminally ill patients in CureLab’s clinical trial are already exceeding the benefits of new drugs recently approved by the FDA.

GenScript’s new GMP-grade GenExact™ single-stranded DNA (ssDNA) and GenWand™ closed-end linear double-stranded DNA (dsDNA) services enable new workflows

Allelica and Invitae want to integrate lifesaving genomic information into breast cancer risk assessments — for the benefit all women

Opalia hits a key go-to-market milestone by eliminating fetal bovine serum from its cell-based milk manufacturing process

Allelica, the leader in Polygenic Risk Scoring, expands scientific advisory board

ZingPR and CubanEight, a top British PR firm with B2B and technology expertise, collaborated to drive numerous media stories about this important development in AI-assisted lung cancer detection and therapeutics.

“… when Elenagen was added to the treatment regimen, all patients showed complete or partial regression of the primary tumor and associated metastases in the lungs, liver, lymph nodes, and bones.”

Optellum’s strategic collaboration agreement with the Lung Cancer Initiative at Johnson & Johnson drives media interest across the board.

This latest patent makes it feasible for CureLab to commence clinical trials aimed at establishing the effectiveness of Elenagen™ and its product variations for treatment of several deadly neurodegenerative diseases.